# ModraDoc006/r in Patients With Breast Cancer

> **NCT03890744** · PHASE2 · COMPLETED · sponsor: **Modra Pharmaceuticals** · enrollment: 12 (actual)

## Conditions studied

- Metastatic Breast Cancer
- Recurrent Breast Cancer

## Interventions

- **DRUG:** ModraDoc006/r

## Key facts

- **NCT ID:** NCT03890744
- **Lead sponsor:** Modra Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-30
- **Primary completion:** 2020-02-13
- **Final completion:** 2020-11-09
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2021-10-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03890744

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03890744, "ModraDoc006/r in Patients With Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03890744. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*